| Bioactivity | CDK9-IN-33 (compound C35) is a potent, selective and orally active CDK9 inhibitor with IC50 values of 17.44, 160, 316.30, 1771.00, >10000 nM for CDK9, CDK7, CDK2, CDK4, CDK6 respectively. CDK9-IN-33 induces apoptosis. CDK9-IN-33 decreases the protein expression of RPB1 CTD Ser2, RPB1, MCL1. CDK9-IN-33 shows anti-tumor activity[1]. |
| Invitro | CDK9-IN-33 (compound C35) (0, 0.01, 0.1, 1 µM; 24 h) 降低 RPB1 CTD Ser2、RPB1、MCL1 的蛋白质表达，并增加裂解 PARP 的表达[1]。CDK9-IN-33 (0, 0.01, 0.1, 1 µM) 降低 MCL1 基因的 mRNA 表达水平[1]。CDK9-IN-33 (0, 0.01, 0.1, 1 µM; 72 h) 以剂量依赖性方式诱导细胞凋亡[1]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only. 0 --> CDK9-IN-33 相关抗体: Cell Proliferation Assay[1] Cell Line: |
| In Vivo | CDK9-IN-33 (10 mg/kg; p.o.; daily for 10 days) 在小鼠中显示出抗肿瘤活性[1]。药代动力学分析[1]。 Cmpd |
| Formula | C23H31N7O2 |
| Molar Mass | 437.54 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Wang WJ, et al. Discovery of Orally Bioavailable and Potent CDK9 Inhibitors for Targeting Transcription Regulation in Triple-Negative Breast Cancer. J Med Chem. 2024 Jun 27;67(12):10035-10056. |